Michael Twomey, MD
Family Medicine · Boise, IDNPI 1073924239
Payments from drug & device makers
Across 94 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$355
- Pfizer$211
- AstraZeneca$187
- AbbVie$138
- Lilly USA, LLC$98
- Boehringer Ingelheim$62
- plus $275 from 15 others
What the payments were for
- Food & beverage$1,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $355 |
| Pfizer | 20 | $211 |
| AstraZeneca | 14 | $187 |
| AbbVie(2 entities) | 7 | $138 |
| Lilly USA, LLC | 7 | $98 |
| Boehringer Ingelheim | 3 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| MDD US Operations, LLC | 2 | $29 |
| GSK | 2 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Bayer | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Gilead | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Merck | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$1,327 in reported general payments places this provider in the 75th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $494 |
| Olmesartan Medoxomil | 17 | $380 |
| Gabapentin | 18 | $324 |
| Atorvastatin Calcium | 29 | $245 |
| Ondansetron Hcl | 11 | $159 |
| Levothyroxine Sodium | 22 | $114 |
| Omeprazole | 16 | $109 |
| Metformin Hcl ErMetformin Hcl | 11 | $80 |
| Losartan Potassium | 15 | $74 |
| Rosuvastatin Calcium | 11 | $50 |
| Lisinopril | 14 | $47 |
| Metoprolol Tartrate | 11 | $44 |
| Amlodipine Besylate | 21 | $44 |
| Alprazolam | 12 | $32 |
| Cyclobenzaprine Hcl | 11 | $21 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Boise
- Brock McConneheyBoise$4.5M
- Diane McConneheyBoise$681K
- Phyllis YouBoise$88K
- John EckBoise$55K
- Kara CadwalladerBoise$24K
- Cyrus VaniaBoise$9K
- Joshua AdamsBoise$8K
- Nicole StiversBoise$7K
- Ammon RobertsBoise$7K
- Mark TurnerMeridian$40.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.